|
⚲
|
| Keyboard |
| Hillhouse Investment Management Ltd
✚
|
|
|---|---|
| CRD # | 160896 |
| SEC # | 801-78022 |
| CIK # | 0001510589 |
| AUM | |
| Employees | 344 (35% Investors, 0% Brokers) |
| Fees | |
| Minimum | |
| Phone | 656-603-0860 |
| Address | 8 Marina Boulevard Singapore, Singapore |
| Source | [IAPD] [EDGAR] [Website] [LinkedIn] [Instagram] |
| Total AUM ($B) |
|---|
| In the News | |
|---|---|
| Fri, 08 May 2026 | Hillhouse Investment Management to acquire Mercer’s Private Client Services — (Re)in Asia |
| Fri, 03 Apr 2026 | Hillhouse Investment Management Opens Office in Abu Dhabi Amid Regional Tensions — Hubbis |
| Fees and Compensation — Form ADV Part 2A (3/31/2023) [Brochure] |
|---|
5, “Fees and Compensation” above for information regarding how HIM is compensated by its clients, the conflict of interest created by allocating investment opportunities among clients, and how HIM addresses such conflict of interest. HIM does not recommend or select third-party investment advisers for its clients. None of HIM, HHLR, or any other affiliate receives compensation, directly or indirectly, from any of the others for any recommendation of the other. However, in certain circumstances, clients could enter into joint ventures with third-party managers or other persons with respect to the management of specified portfolio investments or categories of portfolio investments and in connection therewith, such third-party managers or other persons could receive management fees and/or performance-based compensation such as a carried interest in vehicles through which such joint ventures invest. Any compensation of such third- party managers or of joint venture partners that will reduce a client’s returns from the relevant portfolio investments will not offset carried interest or management fees paid to HIM and will increase the cost of the investors’ investment in clients. Warehoused Investment. During the term of a client, the general partner (or similar controlling entity) of such client or any of its affiliates could initially purchase all or part of an investment intended to be made by such client or fund the purchase of, make a cornerstone investment in connection with or provide financing in connection with, all or part of an investment made by such client if, in each such case, the general partner (or similar controlling entity) of such client determines that it would be necessary or appropriate, including from a legal, tax or regulatory standpoint, in order to facilitate the making of such investment by such client. In such situations, it is generally expected that, (a) the general partner (or similar controlling entity) of such client or its affiliate (as applicable) could transfer the relevant warehoused investment to such client or (b) such client could repay the general partner (or similar controlling entity) of such client or its affiliate (as applicable) for such funding or financing, typically at a price or in an amount (as applicable) generally equal to the cost of such warehoused investment plus interest thereon or on such other terms as permitted under such client’s governing documents. In such cases, such client will pay all closing costs in connection with such warehoused investment, including costs incurred in connection with the transfer of such warehoused investment to such client (if applicable). There is no guarantee, however, that such warehoused investment will be transferred to such client at all (due to legal, tax, regulatory or other reasons), or that the price paid by such client for such warehoused investment would represent the price that would have been obtained in a transaction negotiated at arm’s length. Prior to the initial investment or initial closing of the applicable client, the general partner (or similar controlling entity) of such client or any of its affiliates could purchase, fund the purchase of, make a cornerstone investment in connection with or provide financing in connection with one or more investments to temporarily warehouse such investments for such client. Following the initial investment or closing of such client, the general partner (or similar controlling entity) of such client will use commercially reasonable efforts to procure that the general partner (or similar controlling entity) of such client or its affiliate (as applicable) transfers each such pre-investment or -closing investment to such client at a price equal to the cost of such investment plus interest thereon or on such other terms as permitted under such client’s governing documents. In connection with, or in lieu of, the foregoing, HIM could enter into arrangements with one or more non-affiliated persons (including any existing investors of any client and potential investors in a client) whereby such persons agree to initially fund all or a portion of the cost of such pre-initial investment or pre-closing investments. There is no guarantee, however, that such pre-initial investment or pre-closing investments will be transferred to a client at all (due to legal, tax, regulatory or other reasons), or that the price paid by such client for each such pre-initial investment or pre-closing investment would represent the price that would have been obtained in a transaction negotiated at arm’s length. Other conflicts not discussed above are expected arise in connection with HIM’s advisory business. Investors are urged to consult the offering and other governing documents of the relevant clients. |
| Account Minimums and Types of Clients — Form ADV Part 2A (3/31/2023) [Brochure] |
|---|
ITEM 7: TYPES OF CLIENTS HIM serves as an investment adviser to pooled investment vehicles whose underlying investors are “accredited investors” (as defined in Rule 501(a) of Regulation D under the U.S. Securities Act of 1933, as amended) and/or “qualified purchasers” (as defined in Section 2(a)(51) of the U.S. Investment Company Act of 1940, as amended) and/or “knowledgeable employees” (within the meaning of Rule 3c-5 under the U.S. Investment Company Act of 1940, as amended). Underlying investors in the pooled investment vehicles HIM advises include endowments, foundations, non- profit organizations, pensions, corporates, government entities, family offices, trusts, and other businesses or institutions. As noted in Item 4, HIM and the other Hillhouse Investment Group entities also advise non-U.S. accounts and vehicles (including co-investment vehicles) that are not deemed advisory clients under the Advisers Act and not discussed in this Brochure. HIM could also provide investment advice to institutional clients such as endowments, foundations, non-profit organizations, pensions, corporates, government entities, family offices, trusts, and other businesses or institutions. Minimum Account Size Certain of the Funds require a minimum capital commitment or investment amount, but the general partners of such Funds may accept capital commitments or investment amounts in lesser amounts in their sole discretion. HIM generally does not require clients or investors to maintain a minimum investment to continue an advisory relationship or to remain invested in the Funds. Advisory Agreements HIM’s clients typically enter into a written investment management, advisory, or similar agreement (and/or enter into or become subject to a limited partnership or similar organizational agreement with HIM or one of its affiliates) in establishing an advisory relationship with HIM or its affiliates. HIM will not assign any advisory agreements without client consent. |
| Sector | Form 13F Holdings | Value ($B) | |
|---|---|---|---|
| Pinduoduo Inc | 0.4 | ||
| Alibaba Group Holding Ltd | 0.3 | ||
| BeiGene Ltd | 0.3 | ||
| FUTU Holdings Ltd | 0.2 | ||
| Legend Biotech Corp | 0.1 | ||
| Arrivent Biopharma Inc | 0.1 | ||
| KE Holdings Inc | 0.1 | ||
| Cytek Biosciences Inc | 0.0 | ||
| Marvell Technology Inc | 0.0 | ||
| I-Mab | 0.0 | ||
| View All | |||
| Holdings by Sector ($B) |
|---|
| Type | Form D Funds | Date | Sold | AUM |
|---|---|---|---|---|
| PE | Hillhouse RAVA RAOF II LP | 2026-03-31 | 421.8 M | |
| PE | VNTR Investment LP | 2024-03-29 | 0.8 M | |
| PE | Hillhouse GBT Fund LP | 2023-03-31 | 169.3 M | |
| PE | Hillhouse Hawthorn Venture Opportunities Fund VI LP | 2023-03-31 | 7.4 M | |
| PE | Hillhouse Venture Fund VI LP | 2023-03-31 | 169.7 M | |
| PE | HH HR Investment LP | 2022-03-31 | 25.9 M | |
| PE | Hillhouse Climate Fund LP | 2022-03-31 | 151.7 M | |
| PE | Hillhouse Healthcare Fund LP | 2022-03-31 | 368.0 M | |
| PE | Hillhouse Real Asset Opportunities Fund LP | 2022-03-31 | 397.0 M | |
| PE | Keel Fund I LP | 2022-03-31 | 503.1 M | |
| View All | ||||
| AUM Breakdown | Accounts | AUM ($B) |
|---|---|---|
| By Client Type | ||
| (a) Individuals (other than high net worth individuals) | 0 | 0.0 |
| (b) Individuals (high net worth individuals) | 0 | 0.0 |
| (c) Banking or thrift institutions | 0 | 0.0 |
| (d) Investment companies | 0 | 0.0 |
| (e) Business development companies | 0 | 0.0 |
| (f) Pooled investment vehicles | 71 | 62.0 |
| (g) Pension and profit sharing plans | 0 | 0.0 |
| (h) Charitable organizations | 0 | 0.0 |
| (i) State or municipal government entities | 0 | 0.0 |
| (j) Other investment advisers | 0 | 0.0 |
| (k) Insurance companies | 0 | 0.0 |
| (l) Sovereign wealth funds and foreign official institutions | 0 | 0.0 |
| (m) Corporations or other businesses not listed above | 0 | 0.0 |
| (n) Other | 0 | 0.0 |
| Total | 71 | 62.0 |
| By Discretionary | ||
| Discretionary | 71 | 62.0 |
| Non-Discretionary | 0 | 0.0 |
| Total | 71 | 62.0 |
| By Non-United States Persons | ||
| Non-United States Persons | 62.0 | |
| United States Persons | 0.0 | |
| Total | 71 | 62.0 |
| EDGAR Form | CIK | 2011 - 2026 |
|---|---|---|
| 13F-HR | [0001510589] | |
| 13F-NT | [0001510589] | |
| 3 | [0001510589] | |
| 4 | [0001510589] | |
| SC 13D | [0001510589] | |
| SC 13G | [0001510589] |
| Firm Profile (Form ADV) | |
|---|---|
| Serves | Institutional |
| Fund Types | Hedge Fund, Private Equity |
| LEI | 549300QZBUF1P3XCSP76 |
| Form 3/4/5 Subject | 2011 - 2026 |
|---|---|
| ArriVent BioPharma Inc | |
| HHLR Advisors Ltd | |
| Hillhouse Investment Management Ltd | |
| BeOne Medicines Ltd | |
| Enfusion Inc | |
| Apellis Pharmaceuticals Inc | |
| China Jo-Jo Drugstores Inc |
| Insider Transaction (Form 3/4/5) | Date | Action | Shares | Price | Value ($) |
|---|---|---|---|---|---|
|
ArriVent BioPharma Inc AVBP
Common Stock
|
2025-12-10 | Sell | 555,555 | $23.37 | 12,983,320 |
|
BeOne Medicines Ltd BGNE
Ordinary Shares
|
2024-12-02 | Sell | 17,842,500 | $200.00 | 3,568,500,000 |
|
ArriVent BioPharma Inc AVBP
Series A Preferred Stock · derivative
|
2024-01-30 | Conversion | 55,000,000 | $0.00 | |
|
ArriVent BioPharma Inc AVBP
Common Stock
|
2024-01-30 | Conversion | 3,616,041 | ||
|
ArriVent BioPharma Inc AVBP
Common Stock
|
2024-01-30 | Buy | 555,555 | $18.00 | 9,999,990 |
|
ArriVent BioPharma Inc AVBP
Series B Preferred Stock · derivative
|
2024-01-30 | Conversion | 4,761,903 | $0.00 | |
|
ArriVent BioPharma Inc AVBP
Common Stock
|
2024-01-30 | Conversion | 313,076 | ||
|
BeOne Medicines Ltd BGNE
Ordinary Shares
|
2023-06-14 | Sell | 273,728 | $207.72 | 56,858,780 |
|
BeOne Medicines Ltd BGNE
Ordinary Shares
|
2023-06-13 | Sell | 313,400 | $128.43 | 40,249,962 |
|
BeOne Medicines Ltd BGNE
Ordinary Shares
|
2023-06-13 | Sell | 611,000 | $211.45 | 129,195,950 |
|
BeOne Medicines Ltd BGNE
Ordinary Shares
|
2023-06-12 | Sell | 281,400 | $130.83 | 36,815,562 |
|
BeOne Medicines Ltd BGNE
Ordinary Shares
|
2023-06-12 | Sell | 968,812 | $213.91 | 207,238,575 |
|
BeOne Medicines Ltd BGNE
Ordinary Shares
|
2023-06-09 | Sell | 328,952 | $217.02 | 71,389,163 |
|
BeOne Medicines Ltd BGNE
Ordinary Shares
|
2023-06-09 | Sell | 213,700 | $130.35 | 27,855,795 |
|
BeOne Medicines Ltd BGNE
Ordinary Shares
|
2023-06-08 | Sell | 1,163,825 | $218.14 | 253,876,785 |
|
BeOne Medicines Ltd BGNE
Ordinary Shares
|
2022-08-22 | Other | 7,800 | $0.00 | |
|
Enfusion Inc ENFN
Class A common stock, par value $0.001 per share
|
2021-10-25 | Sell | 647,862 | $15.90 | 10,301,006 |
|
Apellis Pharmaceuticals Inc APLS
Common Stock
|
2017-11-13 | Conversion | 2,098,581 | ||
|
Apellis Pharmaceuticals Inc APLS
Series D Convertible Preferred Stock · derivative
|
2017-11-13 | Conversion | 4,476,275 | $0.00 | |
|
Apellis Pharmaceuticals Inc APLS
Common Stock
|
2017-11-13 | Buy | 1,428,571 | $14.00 | 19,999,994 |
| showing 20 of 24 most recent transactions | |||||